by Raynovich Rod | Jul 23, 2013 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Rayno Life Science: Mid-Day Movers – IBB down 0.9% UP Diagnostics and Tools: Cepheid (CPHD) up 2.55%.Hologic (HOLX) up 3.7%, Response Genetics (RGDX) up 3.2% Biopharmaceuticals: Array (ARRY) up 12.7%, Astex (ASTX) up 2.2%, Viropharma (VPHM) up 1.12% DOWN...
by Raynovich Rod | Jul 18, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
7/19 11:45a EDT Update -Correction Limited to Techs, Biotechs Surge Tech correction continues with XLK down 1.5% but more money finding its way into biotech “bubblet” with IBB ($195) up 1.6%.Leading sectors are energy, healthcare and industrial with...
by Raynovich Rod | Jul 16, 2013 | Biopharmaceuticals
Biotech Stocks Take A Breather: NASDAQ off 0.3% at 3597 A little profit taking has set in after it seemed that the market would roar all summer. From the action in mid-cap biopharma stocks it looks like hedge funds are taking some off among high flyers.NASDAQ has been...
by Raynovich Rod | Jul 11, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Strong NASDAQ Up 1.35%-IBB Hits 188.82 All Time High A stealth rally that began with futures after the close yesterday was triggered by Bernanke comments interpreted by the market as backtracking on “tapering”. Maybe Bernanke was trying to soften his...
by Raynovich Rod | Jul 10, 2013 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Rayno Life Science Movers 2% or more Alexion (ALXN $97.8) up 2.14% Amgen (AMGN $100.71) up 2.4% Pharmacyclics (PCYC $100.55) up 12% Vermillion (VRML $2.90) up 10.6% After a 4 day S&P rally up 2.7% stocks are taking a rest but the IBB ($183.56) rallied another...
by Raynovich Rod | Jul 8, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Life Science Stocks Are Mixed-Biopharma Weak But Diagnostics Strong The life science sector traded along with NASDAQ today so as the NAZ sold off (tech stock weakness) biotech followed. The IBB (181.51) off 0.58% could not regain momentum as of mid-day trading after a...
by Raynovich Rod | Jul 2, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotechnology Sector (IBB 178) Up Over 30% YTD Many Rayno Focus Stocks Outperformed the Market NASDAQ 3431 , S&P 1615 Biopharmaceutical-Top 5 Stocks- % Up YTD Albany Molecular (AMRI) 140.7 Alkermes (ALKS) 59.3 Astex (ASTX) up 49.5 Biogen Idec (BIIB) up 48.9...
by Raynovich Rod | Jul 1, 2013 | Biopharmaceuticals
Biotech Sector All Green Triggered By ONXX Bid A lagging biotech sector perked up today on the $10B bid for ONXX by Amgen(AMGN). Most Rayno Life Science stocks were up except Amgen which was down 0.19%. This is a tradable rally but one not likely to drive the sector...
by Raynovich Rod | Jun 27, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Bond Market Stabilizes A strong bond auction today for the 7 Year Treasury at an interest rate of 1.94% helped support the three day rally easing investor concerns about rising interest rates and liquidation of bonds. European and Japanese stocks were also up. Bond...
by Raynovich Rod | Jun 25, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Global Economic Picture Not Good-Healthcare A Laggard on Rally Day Strong housing and durable goods data supported the rally today taking the S&P up 0.95% and NASDAQ up 0.82%. Comments from the China’s Central Bank helped a recovery from a free fall in the...
